IDEAYA Biosciences, Inc.
IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methyltā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$35.88
Price+1.10%
$0.39
1Y
Price
Market Cap
$3.145b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+57.9%
EBITDA Margin+57.4%
Net Profit Margin+68.4%
Free Cash Flow MarginRevenue
$214.834m
+2969.1%
1y CAGR+948.3%
3y CAGR+731.8%
5y CAGREarnings
-$160.737m
+41.4%
1y CAGR-64.7%
3y CAGR-53.0%
5y CAGREPS
-$1.86
+44.6%
1y CAGR-21.6%
3y CAGR-16.4%
5y CAGRBook Value
$1.092b
$1.185b
Assets$93.102m
Liabilities$27.245m
DebtDebt to Assets
2.3%
-0.2x
Debt to EBITDAFree Cash Flow
-$105.394m
+58.1%
1y CAGR-28.5%
3y CAGR-35.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company